Global deployment Hemex Health has already achieved multi-country usage of its Gazelle Hb Variant Test through collaboration with Case and partners like CWRU, with a growing footprint across over 40 countries, signaling a ready market for expansion via international distributors and procurement programs.

FDA recognition The Breakthrough Device Designation from the FDA for Gazelle Hb Variant Test reinforces regulatory credibility and accelerates adoption, providing a strong talking point for engaging hospitals, clinics, and public health programs seeking high-impact diagnostics with faster regulatory pathways.

Investors & partners Recent investment from Ideaship LLC and strategic collaboration with Tata Elxsi indicate rising investor and corporate interest, creating opportunities for co-marketing, distribution agreements, and co-development of complementary tests or platforms.

Affordability focus The company emphasizes low-cost, point-of-need diagnostics tailored for the developing world, aligning with procurement and global health initiatives that prioritize cost-per-test upside, upcoming tenders, and grant-funded programs for widespread screening of hemoglobin disorders.

Future platform sell-in Gazelle platform advancement for rapid hemoglobin disorder diagnostics positions Hemex to cross-sell into existing lab networks, mobile clinics, and NGO health programs, with upsell opportunities to expand into malaria and sickle cell testing in malaria-endemic regions.